Senseonics Holdings, Inc. Common Stock Q4 2024 Earnings Report

Senseonics Holdings, Inc. Common Stock EPS Results

• Actual EPS: -$2.40
• Consensus EPS: -$0.60
• Beat/Miss: Missed by -$1.80
• One Year Ago EPS: -$1.40

Senseonics Holdings, Inc. Common Stock Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Senseonics Holdings, Inc. Common Stock Announcement Details

• Quarter: Q4 2024
• Date: 3/3/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Senseonics Holdings, Inc. is a medical technology company focused on developing and commercializing continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to measure glucose levels continuously and provide data through a wearable transmitter and mobile application, supporting diabetes management and treatment decisions.

The company’s primary product is the Eversense CGM system, which uses a small sensor implanted under the skin and a removable, rechargeable transmitter worn over the sensor. Unlike many conventional CGM systems that require more frequent sensor replacement, Eversense sensors are designed for extended use. The product line has included 90-day and 180-day systems, and the company has also developed Eversense 365, a long-term CGM system intended to operate for up to one year.

Senseonics is headquartered in Germantown, Maryland. The company has worked with Ascensia Diabetes Care to commercialize and distribute Eversense in the United States and other markets. Its products have been made available in the U.S. and select international markets, subject to applicable regulatory approvals. Senseonics’ business is centered on advancing implantable glucose-monitoring technology and expanding access to long-duration CGM systems.